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Abstract  
AIM: Amplification of the Her2/neu gene and overexpression of the Her2/neu protein in gastric 
carcinoma (GC) is a golden criterion for target therapy with trastuzumab (Herceptin). We aim to 
evaluate the immunohistochemical protein expression and amplification of the oncogene Her2/neu 
by FISH technique in the epithelial gastric carcinoma and to compare their association with different 
clinicopathologic parameters aiming at identifying positive cases that may benefit from targeted 
therapy.  
MATERIALS AND METHODS: This study was done on eighty-five tumour tissue samples from 
patients with GC as well as thirty non-malignant lesions (Gastritis, intestinal metaplasia, adenoma 
with low-grade dysplasia, adenoma with high-grade dysplasia). All were immunohistochemically 
stained with Her2/neu antibody.  
RESULTS: All equivocal and some selected GC cases were submitted for FISH technique to detect 
Her2/neu gene amplification. By immunohistochemistry twenty-three cases (27%) were defined as 
positive for Her2/neu gene amplification and/or protein overexpression. The levels of Her2/neu 
positive (3+), Her2/neu equivocal (2+) and Her2/neu negative (1+/0) were measurable in 14.2%, 
32.9% and 52.9% of the samples, respectively. FISH showed that Her2/neu gene was amplified in 
22 cases, 10 Her2/neu positive (3+), 11 (39.3%) Her2/neu equivocal (2+) and 1 Her2/neu negative 
(1+) cases with IHC staining those who can benefit from anti Her2/neu target therapy. Her2/neu 
was overexpressed positivity (3+) more in intestinal type and mixed carcinoma, and moderately 
differentiated tumours. None of gastritis, intestinal metaplasia or adenoma with low-grade dysplasia 
cases showed positivity for Her2/neu (3+). The Her2/neu positivity (3+) was associated with both 
adenocarcinoma cases and high-grade dysplasia (P = 0.002).  
CONCLUSIONS: The results highlight the necessity of FISH test for further categorization when 
gastric cancer cases are equivocal (2+) by IHC to determine eligibility for the targeted therapy. 
Stepwise increase in the expression of Her2/neu was seen in low-grade dysplasia, high-grade 
dysplasia and carcinoma cases implying its role in cancer evolution. Overexpression of Her 2/neu in 
GC patients can be promising in selecting those who can get beneﬁt from anti-Her2/neu target 
therapy. 
 
 
Introduction 
 
Gastric cancer (GC) is a major cause of 
cancer death worldwide, especially in developing 
countries. The incidence of GC varies from country to 
country, probably as a result of genetic and 
environmental factors [1]. In Egypt, GC is the 12
th 
most common cancer in both sexes representing 
1.6% of the total cancers. It is the 12
th
 leading cause 
of cancer death representing 2.2% of the total cancer 
mortality [2]. This is shown in many Egyptian 
populations- based cancer registries [3]. At the 
Egyptian National Cancer Institute hospital-based 
registry 2002–2010, GC is the 14
th
 most common 
cancer representing 1.8% of cases in both sexes [4]. 
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There is a need to stratify patients with GC 
into the appropriate screening, surveillance, or 
treatment programs. Although histopathology remains 
the most reliable and less expensive method, 
numerous efforts have been made to identify and 
validate novel biomarkers to accomplish the above 
goals. In recent years, several molecules have been 
identified and tested for their clinical relevance in GC 
management, with the exception of Her2/neu, none of 
the biomarkers is currently used in clinical practice, 
and some of them were described in single studies 
[5]. 
Despite ongoing advances in the treatment of 
gastroesophageal cancer, prognosis remains poor. 
The best promise to improve this poor survival is 
provided by new targeted agents. Of these, human 
epidermal growth factor receptor 2 (Her2/neu) is 
currently in the spotlight [6].  
Her2/neu is a proto-oncogene located on 
chromosome 17q21 and a member of the human 
epidermal growth factor receptor (EGFR) family. It 
encodes an 185 kD transmembrane tyrosine kinase 
receptor protein that, through dimerization with other 
family members, regulates signal transduction in 
cellular processes including proliferation, 
differentiation, and cellular survival [7]. Many studies 
have indicated a role of Her2/neu in the development 
of various types of human cancer. Her2/neu is 
amplified, in about 10–20 % of breast carcinomas [6], 
in GC have been shown in studies. Her2/neu positivity 
can be detected in approximately 20% of patients, 
which is a characteristic associated with poor 
prognosis [8]. Since the costs for trastuzumab therapy 
are high and side effects are significant, accurate 
selection of eligible patients for this therapy is crucial. 
Her2/neu status is mainly assessed by 
immunohistochemistry (IHC) and chromogenic (CISH) 
or fluorescence in situ hybridization (FISH) [6]. To 
eliminate discrepancies observed between IHC and 
FISH, Hofmann et al. [9] established an IHC scoring 
system specific for GC. In an international consensus 
meeting, modifications to the breast scoring system 
were made mainly based on the more frequent 
basolateral (incomplete) membrane staining and 
heterogeneity in GC.  
The aim is to evaluate the 
immunohistochemical protein expression and 
amplification of the oncogene Her2/neu by FISH 
technique in the epithelial gastric carcinoma and to 
compare and detect their association with different 
clinicopathologic parameters aiming at identifying 
positive cases that may benefit from targeted therapy. 
 
 
Material and Methods 
 
Eighty-five cases of carcinoma of the stomach 
were collected from archived tissue samples from the 
Surgical Pathology Department of Theodor Bilharz 
Research Institue (TBRI) for patients who had 
undergone total, subtotal or partial gastrectomy was 
evaluated for Her2/neu status using IHC analysis . In 
addition to this, 9 endoscopic gastric biopsies for 
patients with gastritis were also included in the study. 
None of the patients had undergone prior preoperative 
radiation, chemotherapy or targeted therapy.  
Of the 85 cases, 40 cases were selected with 
intestinal-type gastric adenocarcinoma with different 
grades and stages and were compared using 
immunohistochemical analysis to 30 other tissue 
samples in the form of 4 cases of intestinal 
metaplasia, 10 cases of adenoma with low grade 
dysplasia, and 7 cases of adenoma with high grade 
dysplasia that were isolated from juxta tumoral tissues 
in addition to the 9 endoscopic gastric biopsies with 
gastritis. Based on the outcome of the 
immunohistochemical analysis of Her2/neu protein in 
the 85 cases of gastric carcinoma, 40 cases were 
evaluated for the Her2/neu gene status using the 
FISH technique, all cases with equivocal Her2/neu 
protein expression (score 2+) to detect gene status 
and document eligibility for targeted therapy (28 
samples), 10 randomly selected cases with positive 
Her2 protein expression (score 3+) and only 2 
randomly selected cases negative for protein 
expression (score 1+). 
  
Histopathological study 
Paraffin blocks containing representative 
samples of the tumours were selected by reviewing all 
of the available H&E stained slides. The Lauren 
classification of gastric cancer was followed to 
subgroup all cases in histopathology according to 
Lauren [10]. 
The patient demographics and pathologic 
information were retrieved from each pathology report 
including Personal data, Clinical data; Tumor 
localisation, type of surgery, tumour type and grade, 
depth of invasion, the number of lymph nodes 
resected and the number of lymph nodes with 
metastases and final pathological diagnosis. All 
stomach cancers with a midpoint in the stomach lying 
more than 5 cm distal to the EGJ, or those within 5 cm 
of the EGJ but not extending into the EGJ or 
esophagus, are staged using the gastric (not-EGJ) 
cancer staging system set out in the 7th edition of the 
American Joint Committee on Cancer staging, and 
cancers whose midpoint is in the lower thoracic 
esophagus, EGJ, or within the proximal 5 cm of the 
stomach (cardia) that extend into the EGJ or 
esophagus are staged as adenocarcinoma of the 
esophagus [11]. 
Tumours are graded according to WHO 
grading system into well differentiated, moderately 
differentiated and poorly differentiated [12]. 
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Immunohistochemical technique 
Immunohistochemistry for Her2/neu was 
performed on sections cut from the paraffin blocks 
with a commercially available rabbit monoclonal Anti-
human Her2/neu antibody (CELL MARQUE SP3, 
USA). Briefly, samples were sectioned at 4 μm onto 
positively charged slides (Superfrost plus, Menzel-
Glaser, Germany) and the slides were stained on an 
automated platform the Dako autostainer Link 48. 
Heat-induced antigen retrieval was used for 30 min at 
97°C in the high-PH EnVision™ FLEX Target 
Retrieval Solution and the primary antibody was used 
at a dilution of 1 in 100. 
 
Interpretation of immunostaining 
Immunostaining of Her2/neu was performed 
and scored according to the revised scoring criteria of 
Hofmann et al. (9) used in the ToGA trial, which was 
based on the intensity of membrane staining and 
quantity of positive neoplastic cells on a scale of 0-3. 
A score of 0 or 1+ was considered negative while 
scores 2+ was considered equivocal and 3+ was 
positive. Heterogeneous Her2/neu expression was 
considered if the tumour shows the presence of both 
Her2/neu-positive and Her2/neu-negative 
subpopulations of carcinoma cells in a single tumour 
[13]. All immunostained slides were analysed using 
Zeiss microscope with high resolution (Axioscope, 
Germany) at different powers (x 50, x 100, x 200, x 
400). 
 
Gene expression of Her2 by 
fluorescence in situ hybridization 
FISH analysis was used on a representative 
proportion of the tissue, using the Path Vision kit 
(Abbott Laboratories. Abbott Park, IL, USA). All 
samples with positive HER2 protein expression were 
evaluated using labelled probes for both fluorophores, 
i.e., Vysis CEP 17 17p11.1-q11.1 Alpha Satellite DNA 
Spectrum Green, and Vysis LSI HER-2/neu 17q11.2-
12 Spectrum Orange.  
Paraffin was removed from 4 μ tissue sections 
by washing the slides in xylene for ten min, then in 
100% alcohol for five min twice, then air drying them. 
Slides were then immersed in pretreatment solution at 
80°c for 15 minutes, and then tissue sections were 
digested with protease solution by immersing slides in 
solution at 37°C for five minutes. Slides were air dried 
for 2‒5 minutes. Tissue sections were post-fixed in 
10% neutral buffered formalin at room temperature for 
10min before dehydration in ascending grades of 
alcohol and air drying, Tissue sections were 
denatured in the denaturation solution at 72°C for five 
min. Then in ascending grades of alcohol 70%, 95%, 
100% alcohol for one min. each, air dried for 2‒5 
minutes. Probes for the pericentromeric region of 
chromosome 17 (Spectrum Green™) and the locus-
specific probe for Her2 (Spectrum Orange™) were 
used. For each section, one μl of each probe was 
added to seven μl hybridization mix (50% formamide, 
2 × SSC, 10% dextran sulphate) and one μl deionized 
water and denatured in a water bath at 72°C for 
five min and then hybridised overnight at 37°C. Post-
hybridization washes were done by immersing slides 
in pre-warmed 2X SSC/0.3% NP-40 at 73.1ºC, for 
two mins. Slides were air dried in darkness. Slides 
were mounted in 10μl diaminido phenyl indole (DAPI)/ 
antifade. Control sections of normal stomach 
and Her2 amplified breast tumours were included in 
each run.  
 
Interpretation of FISH 
Slides were viewed with a fluorescence 
microscope (BX51 upright, Olympus Corp, Japan), 
where three areas were identified and in each area, 
20 nuclei were assessed. Chromosome 17 copy 
number and HER2 copy number were assessed for 
each of the 20 nuclei at 1000 magnification. A ratio of 
chromosome 17 copy number over HER2/neu copy 
number was obtained from the 60 nuclei. HER2/neu 
was classified based on the value used in breast 
cancer diagnostics into ‘amplified’ 
(Her2/neu/centromere 17 ratios >2) ‘not amplified’ 
(Her2/neu/centromere17 ratio <2) or polysomy (more 
than 2 green signals. 
 
Statistical analysis 
SPSS for Windows, version 18 was used for 
statistical analysis (IBM corporation, Armonk, new 
York, USA). Means of different groups were compared 
using one-way ANOVA. Comparison between percent 
positive cases was calculated by Chi-Square test. A p-
value of 0.05 was considered of statistical 
significance. 
 
 
Results 
 
Her2/neu expression by IHC 
The patients’ clinicopathological character-
critics of the 85 cases gastric carcinoma are listed in 
(Fig. 1; Table 1). Twelve cases (14.2%) were scored 
as positive for Her2/neu membrane staining (3+), 
32.9% were equivocal (2+), and 52.9% were Her2/neu 
negative (0/1+) (Table2). Her2/neu protein expression 
by IHC in adjacent non-tumor normal appearing 
mucosa was detected in 11/85 (12.9%) of 
gastrectomy specimens. The Her2/neu expression 
was membranous (score 1+ or 2+) (Fig. 2; Tables 2-
3). 
There was a higher Her2/neu positivity (3+) in 
the cases with intestinal type adenocarcinoma and 
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mixed type in relation to diffuse type carcinoma. The 
positivity (3+) in the mixed type was detected in 
intestinal differentiation, not in diffuse areas. The 
mixed type was 20% showed positivity (3+), followed 
by the intestinal type (13%) with no statistical 
difference between different types. 
 
Figure 1: H&E stained gastric adenocarcinoma sections. A) case of 
well differentiated gastric carcinoma; malignant cells show mild 
nuclear anaplasia and arranged in well-formed glands (H&E x 400); 
B), case shows moderately differentiated carcinoma, shows 
papillary architecture with fibrovascular cores covered by malignant 
epithelial cells show moderate nuclear anaplasia (H&E x 200); C) 
case of poorly differentiated gastric carcinoma, malignant cells 
show moderate nuclear anaplasia (H&E x 400); D) case of 
adenoma with high-grade dysplasia, showed irregular glands with 
marked nuclear stratification (H&E x 200) 
 
Her2/neu positivity (3+) was 18% in the 
moderately differentiated tumours and 9.7 % of the 
poorly differentiated tumours with no significance 
difference between them.  
Table 1: The relation between the pathologic parameters and 
Her2/neu protein positivity by IHC in carcinoma cases    
Pathologic data Number 
(%) 
Her2/neu (IHC) ( score 
3+ 
P value 
Positive % 
Histologic type 
Adenocarcinoma;  
intestinal type 
54 (63.5%) 7 (13%) 0.567 
(insignificant) 
 Mixed 20 (23.5%) 4 (20%) 
Diffuse 11 (13%) 1 (9%) 
Histopathological Grade 
Well differentiated 4 (4.7%) 0 (0 %) 0.272 
(insignificant) 
 
Moderately differentiated 50 (58.9%) 9 (18%) 
Poorly differentiated 31 (36.4%)  (9.7%)  
Depth of invasion 
T1 0 3 (0%) 0.499 
(insignificant) T2 14 (16.5%) 4 (28.6%) 
T3 45 (52.9%) 5 (11.1%) 
T4 26 (30.6%) 3 (11.5%) 
Lymph node status 
N0 21 (24.7%) 3 (14.2%) 0.724 
N1 11 (12.9%) 2 (18.2%) (insignificant) 
 N2 25 (29.4%) 4 (16%) 
N3 28 (33%) 3 (10.7%) 
Location of the tumour* 
GEJ 14 (16.6%) 1 (7.1%) 0.575 
(insignificant) 
Gastric 37 (43.5%) 6 (16.2%)  
*40% of samples the location of the tumor was not specified. 
 
Figure 2:  Immunohistochemistry for Her2/neu in gastric sections 
expressed as a brown membranous stain. A) case of moderately 
differentiated gastric carcinoma, malignant glands show visible 
weak Her2/neu protein expression at high power (Score 1+) (IHC, 
DAB, x 400); B) case of moderately differentiated gastric carcinoma, 
malignant glands show moderate membranous basolateral and 
complete Her2/neu protein expression (Score 2+) (IHC, DAB, x 
200); C) case of moderately differentiated gastric carcinoma with 
papillary pattern shows strong membranous staining for Her2/neu 
(Score 3+) (x 200); D) Dysplastic acini with moderate Her2/neu 
expression (Score 2+) in a case of gastric carcinoma (IHC, DAB x 
200) 
 
The positive expression of Her2/neu (3+) was 
associated with moderately differentiated tumours, but 
this correlation is not statistically significant (P = 
0.272). Her2/neu positivity (3+) was found more in the 
tumours with T2 stage (28.6%).  
Table 2: Immunohistochemistry - Fluorescence in-situ 
hybridization concordance in gastric carcinoma cases  
IHC 
FISH Total 
Negative Positive  
Negative 1 (50%) 1 (50%) 2 (100%) 
Equivocal 17 (60.7) 11 (39.3%) 28 (100%) 
Positive 0 10 (100%) 10 (100%) 
Total 18 (45%) 22 (55%) 40 (100%) 
Cross tables; Pearson Chi- Square test; p value = 0.004 (significant). 
 
Her2/neu expression in gastric non-malignant 
lesions were nine cases of endoscopic biopsies 
diagnosed as gastritis, and lesions in adjacent non-
tumorous mucosa in gastrectomy specimens for GC 
cases (four cases of intestinal metaplasia, ten cases 
of adenoma with low-grade dysplasia, and seven 
cases of adenoma with high-grade dysplasia). The 
results of these non-malignant gastric lesions were 
compared to the results of forty adenocarcinoma 
cases (intestinal type), selected from the 85 
carcinoma cases. 
None of gastritis, intestinal metaplasia or 
adenoma with low-grade dysplasia samples showed 
strong cellular membranous positivity of Her2/neu 
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protein (3+). The positivity of Her2/neu (3+) was 
associated with both adenocarcinoma cases (17.5%) 
and a case of high-grade dysplasia (14.3%), this 
correlation was highly significant (P < 0.002) (Table 
3). 
Table 3: Her2/neu protein positivity in cases of gastritis, 
intestinal metaplasia, both low and high-grade dysplasia and 
adenocarcinoma 
Item 
Her2/neu 
Total Negative 
 
Equivocal 
 
Positive 
 
Gastritis 9 (100%) 0 (0%) 0 (0%) 9 
Intestinal Metaplasia 0 (0%) 4 (100%) 0 (0%) 4 
Adenoma with low grade 
dysplasia 
7 (70%) 3 (30%) 0 (0%) 10 
Adenoma with high grade 
dysplasia 
3 (42.85%) 3 (42.85%) 1 (14.3%) 7 
Adenocarcinoma 
TOTAL 
19 (47.5%) 
38 (54.3%) 
14 (35%) 
24 (34.3%) 
7 (17.5%) 
8 (11.4%) 
40 
70 
         Cross tables; Pearson Chi- Square test; p value = 0.002 (highly significant). 
 
 
Her2/neu expression by FISH  
Within the group of cases showed equivocal 
Her2/neu protein expression (2+), 17 cases did not 
display Her2/neu gene amplification, and 11 cases 
(39.3%) showed gene amplification. All cases with 
Her2/neu protein positive expression (3+) displayed 
gene amplification. A negative Her2/neu protein 
expression case (0/1+) showed gene amplification. 
The correlation was statistically significant (Fig. 3). 
 
  
Figure 3:  Fluorescent in situ Hybridization using probes directed 
against Her2/neu in gastric carcinoma (FISH, Her2/neu gene, 
x1000).  A) case of moderately differentiated gastric carcinoma, 
negative for Her2/neu gene amplification, IHC score 2+, Red 
signals (Her2/neu gene), green signals [chromosome enumeration 
probe 17 (CEP17)], blue signals (nuclei stain with DAPI); B) case of 
moderately differentiated gastric carcinoma,  positive for Her2/neu 
gene amplification, showing red clusters (orange arrow) and was, 
IHC score 2+; C) case of moderately differentiated gastric 
carcinoma, positive for Her2/neu gene amplification, showing red 
clusters (orange arrow), and was IHC score 3+ 
After IHC and FISH examination, cases with 
IHC score 3+ or IHC score 2+ with positive gene 
amplification by FISH positive were considered 
positive cases, while cases with IHC score 0, 1+ or 2+ 
without gene amplification were negative cases. 
Considering both IHC and FISH results, there were 23 
of 85 cases included in the study positive for Her2/neu 
(27%), while 62 cases were negative (73%). 
 
 
Discussion 
 
Gastric cancer is not a single disease, but a 
conglomerate of histologically, biologically and 
genetically heterogeneous diseases, conditioned by 
the gradual accumulation of various genetic and 
epigenetic alterations leading to the activation of 
several molecular pathways resulting in markedly 
different responses to the same treatment. In the 
wake of increased molecular pathways underlying the 
breast cancer, more is actually known about the 
biological behaviour of gastric cancer and its intrinsic 
subtypes, particularly the identification of the Her2/neu 
amplified gastric cancer subtype [14]. The first 
randomised Phase III trial (ToGA) showed that 
trastuzumab in combination with conventional 
chemotherapy is superior to conventional 
chemotherapy alone in Her2/neu-positive advanced 
gastric cancer. Therefore, an accurate evaluation of 
Her2/neu status in gastric cancer has become 
increasingly important [15]. We found that intestinal-
type adenocarcinoma accounts 63.5% of our cases, 
which is consistent with the reported data by 
Zeeneldin et al. [16], was 47.6%. Most of our cases 
belong to moderately differentiated tumours (58.9%), 
which is in contrast to the other study, that they 
reported 58.1% of cases belong to tumours with G-III / 
IV [16].  
In our study, 14.2% of GC and GEJ 
carcinoma cases were Her2/neu-positive (score +3) 
by IHC. Her2/neu positivity after FISH examination 
(IHC +3 or IHC +2/FISH positive) was 27%. In the 
ToGA trial, the percentage of Her2/neu-positive (IHC 
3+ or IHC 2+/FISH positive) GC or GEJ cancer 
patients was 22.1% overall and around 10.4% of IHC 
3+ in resected samples [17], Jørgensen [8], found 
19% Her2/neu positivity, Chen et al. (18) and Otsu et 
al. (19) reported a range of 5.1 % to 15.6% for 
Her2/neu overexpression.  
In our research, 13% of intestinal type had an 
expression (3+). In mixed type, 20% were strongly 
positive at intestinal type foci, while only one case of 
diffuse type showed strong positivity [19-23], find a 
prevalence in intestinal type ranging from 6.1% to 
28.57%. The percentage of poorly differentiated 
tumours with Her2/neu overexpression is about half 
the percentage of moderately differentiated tumours. 
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None of the well-differentiated tumours shows 
expression of Her2/neu, while Shan and his 
colleagues [24] found that Her2/neu overexpression in 
the Chinese patient was in 11.1%, 37.5% and 0% in 
well, moderately and poorly differentiated tumours, 
respectively. Similarly, Her2/neu overexpression was 
16%, 20% and 6% of well, moderate and poor 
differentiation respectively in the Indian study [25]. 
Many types of research demonstrate the significant 
association between Her2/neu overexpression and 
tumour differentiation [18]. Others do not find this 
association [26]. These conflicting data may be due to 
different sample sizes and the low prevalence of 
Her2/neu in GC and GEJ adenocarcinoma. 
In the present study, there is a higher 
Her2/neu overexpression in T2 category and N1 
category with no statistically significant correlation 
between them this with an agreement with Kataoka et 
al. [27]- Kunz et al. [28]. In contrast to data reported 
by Liang et al. [29] that Her2/neu positivity significantly 
related to TNM stage of gastric cancer. 
We found 39.3% of equivocal cases have 
Her2/neu gene amplification by FISH, while all studied 
cases score 3+ by IHC showed gene amplification. 
One case showed negative IHC expression for 
Her2/neu protein (Score 1+) revealed gene 
amplification by FISH. These are in agreement with 
Yan et al. [26] and Shan et al. [30]. In the current 
study, Her2/neu gene was amplified in all samples 
with oncoprotein overexpression at 3+ level, which is 
consistent with the reported data by Yan and his 
colleagues [26] and reported in 97.5%, 87.5% and 
73.9 of the score +3 samples in studies conducted by 
Shan et al.[30], Gordon et al. [13] and He et al. [31] 
respectively. 
Coping with our findings, many studies 
enrolled Her2/neu gene amplification in Her2/neu IHC-
negative cases in 1.3%- 22.58% (Yan et al. [26] and 
Gordon et al. [13] and He et al. [31] and Shan et 
al.[30]. Discrepancy between protein expression and 
gene amplification indicates that overexpression of 
Her2/neu in GC, differently from breast cancer, may 
be regulated by several mechanisms, including 
transcriptional activation of other genes or post 
transcriptional events [14], these data highlights the 
need and importance of further clarifying the 
relationship between Her2/neu gene amplification and 
protein overexpression in GC. 
We observed Her2/neu immunoreactivity in 
normal-appearing gastric acini adjacent to a tumour in 
about 13% of the studied gastrectomy specimens.This 
matches with the study done by Zhang et al. [32] in 
Chinese patients samples, which reported Her2/neu 
overexpression in adjacent non-tumorous tissues in 4 
of the 72 gastrectomy specimens of GC. A significant 
difference for Her2/neu overexpression between the 
GC and the non-tumor group was observed (18.1 vs. 
5.6%, P<0.05).Wang et al. [33] showed that patients 
with advanced gastric cancer had Her2/neu 
expression on the adjacent non-tumor stomach 
tissues.  
We found a significant association between 
Her2/neu expression and high-grade dysplasia and 
adenocarcinoma. Thus, a stepwise increase in the 
expression of Her2/neu was seen in low-grade 
dysplasia, high-grade dysplasia and carcinoma. In our 
study, four cases of intestinal metaplasia (100%), 
three cases of adenoma with low-grade dysplasia 
(30%) and three cases of adenoma with high-grade 
dysplasia (42.85%) showed equivocal Her2/neu 
immunostaining (score 2+). Slesak et al. [34] reported 
a high frequency of expression of Her2/neu in the 
chronic gastritis area with intestinal metaplasia in the 
territory of gastric carcinoma. 
Rossi et al. [35] and Hu et al. [36] and Fassan 
et al. [37] described the upregulation of Her2/neu in 
gastric dysplastic lesions. Her2/neu overexpression is 
not an event acquired at a later moment by malignant 
gastric cells, but represents the initial timing of this 
process probably occurring in early stages of 
cancerogenesis with subsequent increase of 
expression proportionally to disease progression, 
making possible the Her2/neu test on either the 
primary tumor or a metastatic tumor with similar 
results of Marano and Roviello [14], that is explain this 
finding. 
In conclusion, Her2/neu expression in 
Egyptian patients was comparable to that in other 
populations; 27% of Egyptian patients with primary 
GC and GEJ adenocarcinoma were Her2/neu-positive 
on IHC and FISH. Her2/neu positivity (3+) was 
common in the mixed, intestinal type and moderately 
differentiated carcinoma. The results highlight the 
necessity of FISH test for further categorization when 
gastric cancer cases are equivocal (2+) by IHC to 
determine eligibility for the targeted therapy. Stepwise 
increase in the expression of Her2/neu was seen in 
low-grade dysplasia, high-grade dysplasia and 
carcinoma cases implying its role in cancer evolution.  
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